Tebao Biotech announced that revenue for the third quarter of 2026 was 896 million yuan, a year-on-year decrease of 7.55%; net profit attributable to shareholders of listed companies was 836,000 yuan, a year-on-year decrease of 99.65%; after deducting non-net profit of 225.471 million yuan, a year-on-year decrease of 90.67%. Revenue for the first three quarters of 2026 was 2,732 billion yuan, up 10.20% year on year; net profit to mother was 477 million yuan, down 28.34% year on year; after deducting non-net profit of 511 million yuan, down 24.13% year on year. In the third quarter, one-time expenses related to the slow hepatitis B pipeline ACT580 and ACT201 BD were paid, and R&D expenses increased dramatically; adjustments to the value-added tax rate for common biological products had an impact on operating income.

Tebao Biotech announced that revenue for the third quarter of 2026 was 896 million yuan, a year-on-year decrease of 7.55%; net profit attributable to shareholders of listed companies was 836,000 yuan, a year-on-year decrease of 99.65%; after deducting non-net profit of 225.471 million yuan, a year-on-year decrease of 90.67%. Revenue for the first three quarters of 2026 was 2,732 billion yuan, up 10.20% year on year; net profit to mother was 477 million yuan, down 28.34% year on year; after deducting non-net profit of 511 million yuan, down 24.13% year on year. In the third quarter, one-time expenses related to the slow hepatitis B pipeline ACT580 and ACT201 BD were paid, and R&D expenses increased dramatically; adjustments to the value-added tax rate for common biological products had an impact on operating income.